Matching articles for "Ditropan XL"

Topical Oxybutynin (Gelnique) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • February 8, 2010;  (Issue 1331)
The FDA has approved the marketing of a 10% topical gel formulation of the muscarinic receptor antagonist oxybutynin chloride (Gelnique - Watson) for treatment of overactive bladder. Oxybutynin is also...
The FDA has approved the marketing of a 10% topical gel formulation of the muscarinic receptor antagonist oxybutynin chloride (Gelnique - Watson) for treatment of overactive bladder. Oxybutynin is also available for this indication as oral tablets, an oral syrup and a transdermal patch.
Med Lett Drugs Ther. 2010 Feb 8;52(1331):10-1 | Show Full IntroductionHide Full Introduction

Solifenacin and Darifenacin for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • March 14, 2005;  (Issue 1204)
Solifenacin succinate (VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide (Enablex - Novartis) have been approved by the FDA for oral treatment of overactive...
Solifenacin succinate (VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide (Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.
Med Lett Drugs Ther. 2005 Mar 14;47(1204):23-4 | Show Full IntroductionHide Full Introduction

Trospium (Sanctura): Another Anticholinergic for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • August 2, 2004;  (Issue 1188)
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available...
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
Med Lett Drugs Ther. 2004 Aug 2;46(1188):63-4 | Show Full IntroductionHide Full Introduction

Oxybutynin Transdermal (Oxytrol) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • May 12, 2003;  (Issue 1156)
A patch formulation of oxybutynin (Oxytrol - Watson) is now available for treatment of overactive bladder. It is claimed to be as effective as the oral drug, with less dry...
A patch formulation of oxybutynin (Oxytrol - Watson) is now available for treatment of overactive bladder. It is claimed to be as effective as the oral drug, with less dry mouth.
Med Lett Drugs Ther. 2003 May 12;45(1156):38-9 | Show Full IntroductionHide Full Introduction

Clarification: Drug Risk in Patients with Glaucoma

   
The Medical Letter on Drugs and Therapeutics • June 11, 2001;  (Issue 1106)
The Medical Letter article on Detrol LA and Ditropan XL (vol.43, page 28, April 2, 2001) stated that these drugs should not be used in patients with glaucoma. That statement is misleading because...
The Medical Letter article on Detrol LA and Ditropan XL (vol.43, page 28, April 2, 2001) stated that these drugs should not be used in patients with glaucoma. That statement is misleading because anticholinergic or antimuscarinic drugs present a risk only to patients with untreated angle-closure (also called narrow-angle) glaucoma, which accounts for 10% of glaucomas in the USA. These drugs have no effect on the more common open-angle glaucoma, or on angle-closure glaucoma that has been treated by laser iridectomy.
Med Lett Drugs Ther. 2001 Jun 11;43(1106):52 | Show Full IntroductionHide Full Introduction

Detrol LA and Ditropan XL

   
The Medical Letter on Drugs and Therapeutics • April 2, 2001;  (Issue 1101)
Direct-to-consumer advertisements are promoting the effectiveness of extended-release formulations of tolterodine tartrate (Detrol LA) and oxybutynin (Ditropan XL) for treatment of overactive ...
Direct-to-consumer advertisements are promoting the effectiveness of extended-release formulations of tolterodine tartrate (Detrol LA) and oxybutynin (Ditropan XL) for treatment of overactive bladder.
Med Lett Drugs Ther. 2001 Apr 2;43(1101):28 | Show Full IntroductionHide Full Introduction